Phase 3 Genmab GCT1184-03 Adv/Rec Endometrial Cancer (GOG-3128)
Phase III Clinical Trial
GCT1184-03: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator�s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Participating Locations